Literature DB >> 10534774

Germline mutations in NF1 patients with malignancies.

R Wu1, C López-Correa, J L Rutkowski, L L Baumbach, T W Glover, E Legius.   

Abstract

We have analyzed 98.5% of the coding region of the NF1 gene at the cDNA level in seven NF1 patients who developed malignant peripheral nerve sheath tumors. Seven germline mutations were detected in six individuals: a 6-bp in-frame deletion in exon 28, a splice acceptor mutation in intron 31 resulting in a premature stop of translation, a missense mutation in exon 38, and three total NF1 gene deletions. In one of the patients with a total NF1 gene deletion, a missense mutation in exon 16 on the other NF1 allele was detected. These data indicate that NF1 patients developing malignant neoplasms can have any type of NF1 germline mutation such as a total gene deletion, a frameshift mutation, an in-frame deletion, or a missense mutation. We conclude that in our series no specific type of NF1 germline mutation was found in NF1 individuals with malignancies, but that large NF1 gene deletions were more frequently found in this group than reported for the general population of NF1 individuals. Genes Chromosomes Cancer 26:376-380, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10534774

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  Molecular diagnosis of neurofibromatosis type 1: 2 years experience.

Authors:  Siân Griffiths; Peter Thompson; Ian Frayling; Meena Upadhyaya
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

Review 2.  Ras-Specific GTPase-Activating Proteins-Structures, Mechanisms, and Interactions.

Authors:  Klaus Scheffzek; Giridhar Shivalingaiah
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

3.  Unequal meiotic crossover: a frequent cause of NF1 microdeletions.

Authors:  C López Correa; H Brems; C Lázaro; P Marynen; E Legius
Journal:  Am J Hum Genet       Date:  2000-04-20       Impact factor: 11.025

4.  Elevated risk for MPNST in NF1 microdeletion patients.

Authors:  T De Raedt; H Brems; P Wolkenstein; D Vidaud; S Pilotti; F Perrone; V Mautner; S Frahm; R Sciot; E Legius
Journal:  Am J Hum Genet       Date:  2003-03-26       Impact factor: 11.025

5.  Identification of genes potentially involved in the increased risk of malignancy in NF1-microdeleted patients.

Authors:  Eric Pasmant; Julien Masliah-Planchon; Pascale Lévy; Ingrid Laurendeau; Nicolas Ortonne; Béatrice Parfait; Laurence Valeyrie-Allanore; Karen Leroy; Pierre Wolkenstein; Michel Vidaud; Dominique Vidaud; Ivan Bièche
Journal:  Mol Med       Date:  2010-09-10       Impact factor: 6.354

6.  MicroRNA-21 correlates with tumorigenesis in malignant peripheral nerve sheath tumor (MPNST) via programmed cell death protein 4 (PDCD4).

Authors:  Satoru Itani; Toshiyuki Kunisada; Yuki Morimoto; Aki Yoshida; Tsuyoshi Sasaki; Sachio Ito; Mamoru Ouchida; Shinsuke Sugihara; Kenji Shimizu; Toshifumi Ozaki
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-22       Impact factor: 4.553

7.  Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain.

Authors:  R Fahsold; S Hoffmeyer; C Mischung; C Gille; C Ehlers; N Kücükceylan; M Abdel-Nour; A Gewies; H Peters; D Kaufmann; A Buske; S Tinschert; P Nürnberg
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

Review 8.  Management of childhood malignant peripheral nerve sheath tumor.

Authors:  Andrea Ferrari; Gianni Bisogno; Modesto Carli
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 9.  Connective tissue dysplasia in five new patients with NF1 microdeletions: further expansion of phenotype and review of the literature.

Authors:  K A Mensink; R P Ketterling; H C Flynn; R A Knudson; N M Lindor; B A Heese; R J Spinner; D Babovic-Vuksanovic
Journal:  J Med Genet       Date:  2006-02       Impact factor: 6.318

10.  Discontinuing financial incentives for adherence to antipsychotic depot medication: long-term outcomes of a cluster randomised controlled trial.

Authors:  Stefan Priebe; Stephen A Bremner; Hana Pavlickova
Journal:  BMJ Open       Date:  2016-09-21       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.